创胜集团
TRANSCENTA

Transcenta Holding Limited
創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON STRATEGIC COLLABORATION AGREEMENT WITH IVD MEDICAL HOLDING LIMITED AND ITS TWO SUBSIDIARIES TO EXPLORE FIRST-OF-ITS-KIND OFFERING OF REAL-WORLD ASSET TOKENS TO POTENTIALLY FUND DEVELOPMENT OF INNOVATIVE ONCOLOGY TREATMENTS

- ***Future proceeds in case of successful offering of tokens will fund the accelerated clinical and preclinical development of multiple innovative oncology antibody assets***
- ***Innovative financing model capitalises on recent regulatory reforms to democratize access to innovative investment opportunities via blockchain***

This announcement is made by Transcenta Holding Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but not otherwise defined shall have the same meaning ascribed thereto in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the "**Board**") is excited to announce that on September 21, 2025, the Company and Transcenta Oncology Inc. ("**Transcenta Oncology**"), a wholly owned subsidiary of the Company, had entered into a non-binding strategic collaboration agreement (the "**Collaboration Agreement**") with IVD Medical Holding Limited (shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 1931) and its two subsidiaries, ETHK Inc. and ETHK HOLDINGS LIMITED (collectively known as "**ETHK**"). Pursuant to the Collaboration Agreement, the parties have agreed to strategically collaborate and explore the potential issuance of Real-World Asset Tokens on the Ethereum blockchain to fund the preclinical and clinical development of one or more selected programs from among six of the potentially first-in-class and/or best-in-class oncology treatments. This first-of-its-kind financing strategy in biotechnology, enabled by recent regulatory reforms in both the United States and China, upon successful completion, will support accelerated development of innovative medicines, more cost-effective capital fundraising and expanded access to innovative investment opportunities beyond the traditional institutional ecosystem.

"We are excited to explore this first-of-its-kind blockchain-based financing to accelerate the development of our innovative early oncology portfolio," said Dr. Xueming Qian, Founder, Chairman and CEO of the Company. "Thanks to the forward-looking regulatory policies championed by the authorities in both the U.S. and China, we are pleased to lead the way in democratizing investment in biotechnology innovation and accelerating development of potential new treatments for patients."

In the event of a successful tokens issuance (subject to compliance with applicable laws and regulations), the proceeds from this collaboration will support the development of one or more selected programs from among the following six innovative oncology programs:

- **TST005:** A bispecific antibody targeting PD-L1 and TGF-β that currently has completed dose escalation study in both the U.S. and China; and it has demonstrated in preclinical significantly better anti-tumor activities relative to checkpoint inhibitors alone, especially in tumors with high TGF-β, along with a favorable safety and tolerability profile;

- **TST003:** A monoclonal antibody targeting GREMLIN-1 that currently has completed phase 1 dose-escalation study in both the U.S. and China. GREMLIN-1 has been implicated in promoting metastasis and negatively correlating with overall survival in multiple cancers. TST003 has demonstrated significant anti-tumor activities both *in vitro* and in *vivo* as monotherapy in PD1-resistant esophageal cancer and colorectal cancer models, and in combination with androgen-deprivation therapy in prostate cancer;

- **TST786:** A trispecific antibody targeting PD-1 and VEGF, clinically validated in multiple tumors, as well as GREMLIN-1, a protein promoting tumor growth and metastasis, currently in preclinical stage. TST786 is designed to inhibit metastasis and potentially improve on the survival benefits observed with PD-1xVEGF bispecific agents;

- **TST105:** A bispecific antibody drug conjugate targeting FGFR2b and another undisclosed antigen in preclinical stage. This bispecific ADC has preferential binding to FGFR2b expressing tumor cells and with site-specific conjugation and a moderate cytotoxicity payload to provide improved efficacy and safety over earlier naked antibodies;

- **TST106:** A bispecific antibody drug conjugate targeting CLDN18.2 and another undisclosed antigen in preclinical stage. This bispecific ADC has preferential binding to CLDN18.2 expressing tumor cells and a moderate cytotoxicity to enhance the therapeutic index of earlier CLDN18.2-targeted treatments, while potentially improving efficacy and safety; and

- **TST013:** A monospecific antibody drug conjugate targeting LIV-1 in preclinical stage. LIV-1 is a clinically validated biomarker in multiple tumors. TST013 has exhibited with improved affinity to LIV-1 expressing tumor cells, silenced Fc binding and a more potent payload designed to overcome resistance to earlier lines of treatment.

About Transcenta Oncology

Transcenta Oncology Inc. is a Delaware-registered, wholly-owned subsidiary of the Company, dedicated to transcending today's cancer care by rapidly developing novel biologics against clinically validated targets.

Cautionary statement: There is no guarantee that any of TST005, TST003, TST786, TST105, TST106 and TST013 will be developed, or ultimately brought to market, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

GENERAL

Shareholders and potential investors of the Company should note that the Collaboration Agreement only sets out the intentions of the parties to the possible collaboration, and it will not be legally binding. If a legally binding and formal agreement has been agreed and/or signed, the Company will make a further announcement in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and
Chief Executive Officer

Hong Kong, September 22, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.